J Cancer 2017; 8(8):1460-1465. doi:10.7150/jca.18470
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea
Kim BJ, Jang HJ, Kim HS, Kim JH. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer 2017; 8(8):1460-1465. doi:10.7150/jca.18470. Available from http://www.jcancer.org/v08p1460.htm
The expansion of our understanding of tumor immunity and the recent success of new cancer immunotherapy has reignited the hope that we can treat cancer effectively with immunotherapeutic approaches. Immune checkpoint inhibitors have shown significant efficacy in the treatment of some solid and hematologic malignancies. Encouraged by recent success in some other types of malignancies, many clinical trials are ongoing to evaluate the efficacy of immune checkpoint inhibitors in gastrointestinal (GI) malignancies.
In this review, we briefly discuss theoretical background and current status of immune checkpoint inhibitors in GI cancers. We summarize the key studies and present the ongoing clinical trials involving immune checkpoint inhibitors in GI cancers.
Keywords: cancer immunotherapy, gastrointestinal cancer, immune checkpoint inhibitor, review.